Actavia Life Sciences, Inc. (RASP)
OTCMKTS · Delayed Price · Currency is USD
0.0040
-0.0285 (-87.69%)
At close: Jul 22, 2024
Actavia Life Sciences Company Description
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma.
It is developing RASP-201, a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301, an NCE for NPM1, currently at the pre-clinical stage to treat refractory AML with reduced toxicity.
The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023.
Actavia Life Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
Actavia Life Sciences, Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
Contact Details
Address: 5 Penn Plaza New York, Nevada 10001 United States | |
| Phone | 646 396 4087 |
| Website | rasna.com |
Stock Details
| Ticker Symbol | RASP |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| ISIN Number | US7538881068 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Keeren Shah | Chief Financial Officer |
| Willy Jules Simon | Executive Chairman |